| Clay, Timothy |
Argonaut, NCT05480865: SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation |
|
|
| Recruiting | 1 | 85 | Europe, RoW | BBP-398, sotorasib | Navire Pharma Inc., a BridgeBio company, Amgen | Solid Tumor, Adult, Metastatic Solid Tumor, Metastatic NSCLC, Non Small Cell Lung Cancer | 06/24 | 06/25 | | |
| Tan, Peter |
| Active, not recruiting | 3 | 430 | Europe, Canada, US, RoW | Pelabresib, Ruxolitinib, Placebo | Constellation Pharmaceuticals | Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | 08/23 | 12/27 | | |
|
|
|
|
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 05/27 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
BRUIN-MCL-321, NCT04662255: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) |
|
|
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
| Active, not recruiting | 3 | 650 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma | 02/25 | 08/28 | | |
NCT04735575: A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma |
|
|
| Recruiting | 1/2 | 66 | RoW | EMB-06 | Shanghai EpimAb Biotherapeutics Co., Ltd. | Relapsed or Refractory Multiple Myeloma | 12/23 | 03/25 | | |
PXS5505-MF-101, NCT04676529: Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis |
|
|
| Active, not recruiting | 1/2 | 43 | US, RoW | PXS-5505 | Syntara, Parexel | Myelofibrosis | 08/25 | 08/25 | | |
NCT05427812: Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 121 | US, RoW | ISB 1442 SC injection escalating doses, ISB 1442 SC injection at RP2D | Ichnos Sciences SA | Relapsed/Refractory Multiple Myeloma | 05/27 | 05/27 | | |
NCT05003141: PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies |
|
|
| Recruiting | 1a/1b | 110 | US, RoW | PSB202 | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, Refractory B-Cell Lymphoma, MALT Lymphoma | 07/23 | 01/24 | | |
NCT04402541: Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome |
|
|
| Completed | 1 | 55 | US, RoW | CB-5339, CB-5339 Tosylate | Cleave Therapeutics, Inc. | Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndromes | 07/23 | 07/23 | | |
NCT04861779: A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies |
|
|
| Recruiting | 1 | 156 | RoW | HSK29116 | Haisco Pharmaceutical Group Co., Ltd. | Relapsed/Refractory B-Cell Malignancies | 08/23 | 10/23 | | |
WUN101-01, NCT05470140: A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) |
|
|
| Active, not recruiting | 1 | 9 | US, RoW | WU-NK-101 | Wugen, Inc. | Acute Myeloid Leukemia | 10/24 | 01/25 | | |
NCT06127628: Effectiveness of Ultrasound-guided Scalp Block for Supratentorial Craniotomy |
|
|
| Recruiting | N/A | 60 | RoW | Ultrasound-guided scalp block with ropivacaine 0.375% | University Malaysia Sarawak | Pain, Postoperative, Anesthesia | 03/25 | 10/25 | | |
| Kijlstra, Jelle |
NCT05967416: Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 1 | 24 | US | SIRPant-M, External-beam radiotherapy (XRT) | SIRPant Immunotherapeutics, Inc. | Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma | 03/25 | 03/25 | | |
| Ariyapperuma, Mihitha |
NCT04645069: ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors |
|
|
| Completed | 1/2 | 58 | US, RoW | ADG126 Mono, ADG126-anti PD1, ADG126-ADG106 | Adagene Inc | Advanced/Metastatic Solid Tumors | 01/24 | 05/24 | | |
NCT05198752: A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 30 | Europe, RoW | Neoantigen mRNA Personalised Cancer SW1115C3 | Stemirna Therapeutics | Solid Tumor | 12/23 | 06/24 | | |
NCT05498597: AMT-151 in Patients With Selected Advanced Solid Tumours |
|
|
| Recruiting | 1 | 30 | RoW | AMT-151 | Multitude Therapeutics Inc., Tigermed Consulting Co., Ltd | Advanced Solid Tumor, Advanced Cancer, Advanced Carcinoma, Ovarian Cancer, Ovarian Carcinoma, Ovarian Epithelial Cancer, Ovarian Endometrioid Adenocarcinoma, Endometrial Cancer, Endometrial Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Lung Adenocarcinoma, Triple Negative Breast Cancer, Pancreatic Ductal Adenocarcinoma, Malignant Pleural Mesothelioma, Ovarian Clear Cell Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Mucinous Adenocarcinoma | 01/24 | 10/24 | | |
NCT05200013: BAT7104 in Patients With Advanced Solid Tumours |
|
|
| Completed | 1 | 14 | RoW | BAT7104 | Bio-Thera Solutions, George Clinical Pty Ltd | Patients With Advanced Solid Tumors | 06/24 | 06/24 | | |
NCT05650203: A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies |
|
|
| Withdrawn | 1 | 254 | NA | JS009 as a monotherapy and JS009 as a Triple Combination Therapy in Combination with Toripalimab and JS006 | Shanghai Junshi Bioscience Co., Ltd. | Primary Condition: Advanced Tumors | 10/25 | 12/26 | | |
NCT05607498: First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma |
|
|
| Recruiting | 1 | 150 | RoW | EMB07 | EpimAb Biotherapeutics (Suzhou)Co., Ltd. | Advanced/Metastatic Solid Tumors, Relapse/Refractory Lymphoma | 10/25 | 03/26 | | |
